Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2026 | 5-year toxicity following SABR: insights from the SABR-5 trial

Robert Olson • 16 May 2026
ESTRO 2026
General
SABR-5

Robert Olson, MD, BC Cancer, Prince George, Canada, comments on the five-year toxicity data from the SABR-5 trial (NCT02933242) of stereotactic ablative radiotherapy (SABR) in patients with up to 5 oligometastases. Toxicities did persist up to 5 years following treatment, however occurrences of grade 3 or higher toxicities were minimal from 3 years after SABR. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Olson

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
Could the gut microbiome inform radiotherapy outcomes?
0:56
Could the gut microbiome inform radiotherapy outcomes?
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals